LOS ANGELES, June 1, 2010 – Marlin Equity Partners (“Marlin”) is pleased to announce that it has acquired Datafarm, Inc. (“Datafarm”), a leading provider of software and service solutions that support the submissions and approval process for life sciences companies. Datafarm will be integrated with Liquent, a Marlin portfolio company, which was purchased from Thomson Reuters in December 2009.
“Marlin continues to recognize the life sciences industry’s constant challenge with regulatory change, drive for new product approvals and mounting cost pressures. With the acquisition of Datafarm, we are continuing to invest in Liquent to support their evolving strategy to solve the industry’s complex regulatory challenges,” stated Jim Brady, Healthcare Operating Partner at Marlin.
This acquisition further strengthens Liquent’s technical depth and it will now offer the deepest and broadest product suite in the market. In addition, Liquent’s regulatory and clinical outsourcing services team will more than double as a result of this acquisition. Also, the acquisition of Datafarm’s Indian outsourcing operation provides a proven low-cost, off shore capability to complement Liquent’s on shore outsourcing services offerings.
Datafarm’s founder and CEO, Shy Kumar, will join Liquent as its Senior Vice President and Chief Technology Officer. “This merger is consistent with Datafarm’s commitment and strategy to further enhance and expand the availability of global regulatory submission and outsourced service solutions to the life sciences industry. We look forward to combining our outstanding technology and complementary wealth of experience with Liquent,” said Mr. Kumar.
About Marlin Equity Partners
Marlin Equity Partners is a Los Angeles, California-based private investment firm with over $1 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries that are in the process of undergoing varying degrees of operational, financial or market-driven change where its capital base, industry relationships and extensive network of operational resources significantly strengthens a company’s outlook and enhances value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 35 acquisitions. For more information, please visit www.marlinequity.com.
About Liquent, Inc.
Liquent is a Horsham, Pennsylvania-based provider of software and related regulatory and clinical services to the life sciences industry, helping to ensure its clients meet the strict standards of regulatory authorities across the world. Liquent aids clients in the achievement of quality, accuracy and data integrity to deliver regulatory reports and submissions reliably and on time. As a result, life sciences companies rely on Liquent’s solutions to provide the software and services necessary to expedite the regulatory submissions and approval process, improve speed to market, control costs and increase productivity. Over the last decade, thousands of regulatory submissions have been produced using Liquent’s world-class products and expert services. For more information, please visit www.liquent.com.
For additional information, please contact Peter Spasov at (310) 364-0100 or via e-mail at firstname.lastname@example.org.